Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Finerenone by Bayer for Congestive Heart Failure (Heart Failure): Likelihood of Approval
Finerenone is under clinical development by Bayer and currently in Phase III for Congestive Heart Failure (Heart Failure). According to...
Regorafenib by Bayer for Rhabdomyosarcoma: Likelihood of Approval
Regorafenib is under clinical development by Bayer and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...
BAY-2862789 by Bayer for Non-Small Cell Lung Cancer: Likelihood of Approval
BAY-2862789 is under clinical development by Bayer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Anetumab ravtansine by Bayer for Fallopian Tube Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
Anetumab ravtansine by Bayer for Uterine Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
Anetumab ravtansine by Bayer for Endometrial Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
Anetumab ravtansine by Bayer for Metastatic Pancreatic Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
BAY-3389934 by Bayer for Bleeding And Clotting Disorders: Likelihood of Approval
BAY-3389934 is under clinical development by Bayer and currently in Phase I for Bleeding And Clotting Disorders. According to GlobalData,...
BAY-2862789 by Bayer for Solid Tumor: Likelihood of Approval
BAY-2862789 is under clinical development by Bayer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
BAY-2416964 by Bayer for Pancreatic Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
BAY-2416964 by Bayer for Colorectal Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
BAY-2416964 by Bayer for Breast Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Breast Cancer. According to GlobalData, Phase I...
BAY-2701250 by Bayer for Pulmonary Hypertension: Likelihood of Approval
BAY-2701250 is under clinical development by Bayer and currently in Phase I for Pulmonary Hypertension. According to GlobalData, Phase I...
Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease by Bayer for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Drug to Inhibit Prolylendopeptidase (PREP) for Chronic Obstructive Pulmonary Disease is under clinical development by Bayer and currently in Phase...
Emodepside by Bayer for Ancylostomiasis (Hookworm Infections): Likelihood of Approval
Emodepside is under clinical development by Bayer and currently in Phase II for Ancylostomiasis (Hookworm Infections). According to GlobalData, Phase...
BAY-2416964 by Bayer for Non-Small Cell Lung Cancer: Likelihood of Approval
BAY-2416964 is under clinical development by Bayer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Runcaciguat by Bayer for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
Runcaciguat is under clinical development by Bayer and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData,...
Anetumab ravtansine by Bayer for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...
Risk adjusted net present value: What is the current valuation of Bayer's Elinzanetant?
Elinzanetant is a small molecule commercialized by Bayer, with a leading Phase III program in Vasomotor Symptoms of Menopause (Hot...
Asundexian by Bayer for Myocardial Infarction: Likelihood of Approval
Asundexian is under clinical development by Bayer and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II...